<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Increased levels of serum prolactin have been reported in patients with various <z:hpo ids='HP_0002960'>autoimmune diseases</z:hpo> and have been associated with <z:e sem="disease" ids="C0024141" disease_type="Disease or Syndrome" abbrv="">lupus disease</z:e> activity </plain></SENT>
<SENT sid="1" pm="."><plain>Currently, there is a lack of data regarding <z:hpo ids='HP_0000870'>hyperprolactinaemia</z:hpo> in patients with the <z:e sem="disease" ids="C0085278" disease_type="Disease or Syndrome" abbrv="">antiphospholipid syndrome</z:e> </plain></SENT>
<SENT sid="2" pm="."><plain>Hence, this study was carried out in order to evaluate the prevalence and clinical significance of <z:hpo ids='HP_0000870'>hyperprolactinaemia</z:hpo> in <z:e sem="disease" ids="C0085278" disease_type="Disease or Syndrome" abbrv="">antiphospholipid syndrome</z:e> </plain></SENT>
<SENT sid="3" pm="."><plain>A total of 172 European patients with <z:e sem="disease" ids="C0085278" disease_type="Disease or Syndrome" abbrv="">antiphospholipid syndrome</z:e> and 100 geographically and sex-matched healthy controls were included in the study; none had obvious causes of <z:hpo ids='HP_0000870'>hyperprolactinaemia</z:hpo> </plain></SENT>
<SENT sid="4" pm="."><plain><z:hpo ids='HP_0000001'>All</z:hpo> patients underwent clinical assessment for disease manifestations, in addition to laboratory assessment for serum prolactin, <z:hpo ids='HP_0003613'>antiphospholipid antibodies</z:hpo> and some other biomarkers of <z:hpo ids='HP_0002960'>autoimmune diseases</z:hpo> </plain></SENT>
<SENT sid="5" pm="."><plain>The tests were performed utilizing the LIAISONÂ® Analyzer (DiaSorin, Sallugia Italy) </plain></SENT>
<SENT sid="6" pm="."><plain><z:hpo ids='HP_0000870'>Hyperprolactinaemia</z:hpo> was detected in 21/172 patients with <z:e sem="disease" ids="C0085278" disease_type="Disease or Syndrome" abbrv="">antiphospholipid syndrome</z:e> and 0/100 controls (p &lt; 0.001) </plain></SENT>
<SENT sid="7" pm="."><plain>This significant difference was present in both genders and was obvious even after subgrouping the patients into primary and <z:e sem="disease" ids="C0409983" disease_type="Disease or Syndrome" abbrv="">secondary antiphospholipid syndrome</z:e> </plain></SENT>
<SENT sid="8" pm="."><plain>When clinical features were compared, <z:hpo ids='HP_0000870'>hyperprolactinaemia</z:hpo> was associated with reproductive failure, including early and <z:e sem="disease" ids="C0878751" disease_type="Disease or Syndrome" abbrv="">late pregnancy</z:e> loss (p &lt; 0.05), as well as <z:hpo ids='HP_0001511'>intrauterine growth retardation</z:hpo> (p &lt; 0.05) </plain></SENT>
<SENT sid="9" pm="."><plain><z:hpo ids='HP_0000870'>Hyperprolactinaemia</z:hpo> was negatively related to <z:hpo ids='HP_0002829'>arthralgias</z:hpo>, <z:hpo ids='HP_0004936'>venous thrombosis</z:hpo>, pulmonary microthrombosis, <z:hpo ids='HP_0002092'>pulmonary hypertension</z:hpo> in both <z:e sem="disease" ids="C0409980" disease_type="Disease or Syndrome" abbrv="">primary antiphospholipid syndrome</z:e> and <z:e sem="disease" ids="C0085278" disease_type="Disease or Syndrome" abbrv="">antiphospholipid syndrome</z:e> secondary to other diseases, and to neurological manifestations in <z:e sem="disease" ids="C0409980" disease_type="Disease or Syndrome" abbrv="">primary antiphospholipid syndrome</z:e> (p&lt;0.05) </plain></SENT>
<SENT sid="10" pm="."><plain>The data indirectly imply that prolactin may play a role in the pathogenesis of <z:e sem="disease" ids="C0085278" disease_type="Disease or Syndrome" abbrv="">antiphospholipid syndrome</z:e>, especially <z:e sem="disease" ids="C0085278" disease_type="Disease or Syndrome" abbrv="">antiphospholipid syndrome</z:e>-related reproductive failure </plain></SENT>
</text></document>